Smoke without fire? Researchers question heated tobacco products

Industry Insight
Jul.22.2022

Heated tobacco products have soared in popularity as a "smoke free" alternative to cigarettes in recent years, but a peer-reviewed report has suggested their emissions could be considered smoke—a claim strongly rejected by the tobacco industry.

 

Smoke without fire? Researchers question heated tobacco products

Heated tobacco products, or HTPs, are often confused with e-cigarettes, which heat liquid that can contain nicotine but do not involve tobacco leaf.

HTPs instead use a high heat to decompose tobacco, via a process called pyrolysis, which does not set it on fire or burn it, therefore avoiding creating smoke.

 

The most popular and widely available HTP, Philip Morris International's IQOS, is an electronic device that heats a tobacco-filled, paper-wrapped, cigarette-like stick at a temperature of up to 350 degrees Celsius (662 degrees Fahrenheit).

 

Last month a review of the available research by experts in pyrolysis from Britain's Nottingham University found "chemical evidence that IQOS emissions fit the definition of both an aerosol and smoke."

 

The paper, published in the American Chemical Society's Omega journal, was funded by the STOP anti-tobacco initiative.

Its lead author Clement Uguna said that IQOS emissions contain chemical compounds that are "in normal tobacco smoke, bush burning and wood smoke".

 

"Hence smoke arises simply by heating organic substances and does not necessarily involve fire," he told AFP.

 

The paper also found that previous research on IQOS—the majority of which has been funded by the tobacco industry—had compared a stick to a typical cigarette.

 

However IQOS sticks are much smaller, containing around 200 milligrams of tobacco compared to 645 milligrams for a standard cigarette, it said.

 

Because research by Philip Morris International (PMI) did not use a "like against like" comparison, it "underestimated" the levels of harmful and potentially harmful constituents (HPHCs) from IQOS, the review added.

 

PMI said the level of HPHCs in IQOS emissions—per stick—was "reduced on average by 90-95 percent compared to cigarette smoke".

 

However that level fell to 68 percent when comparing the tobacco content of the two products, the Nottingham University experts said, calling for more research.

 

'Not smoke': PMI

 

PMI told AFP that the paper "misleadingly leverages pieces of the scientific assessment while omitting other important pieces of evidence".

 

"Numerous international combustion experts and a number of government agencies have reviewed the same evidence package and concluded that the IQOS aerosol produced is not smoke," it said.

 

Reto Auer, a doctor at Germany's University of Bern who has previously researched heated tobacco, praised the Omega paper, telling AFP it was "one of the rare reports to dare to tackle the question of 'smoke' so deeply".

 

Jamie Hartmann-Boyce of the Centre for Evidence-Based Medicine at Oxford University, an author of a highly regarded review on HTP science published earlier this year, said the "important" paper "made some very good points".

 

"I think mechanistically there are a lot of reasons to suspect HTPs might be more harmful than e-cigarettes and possibly less harmful than traditional cigarettes—but we really need more data," she told AFP.

 

'Difficult balance'

 

IQOS is available in more than 60 countries under widely varying regulations, and sticks come in flavours such as menthol, cherry and grape, which critics say help attract younger users.

 

Last month the European Commission proposed banning flavoured HTP varieties after stick sales in the EU soared more than 2,000 percent—from 934 million to nearly 20 billion—between 2018 and 2020.

 

PMI told AFP that the "proposal from the Commission is not underpinned by evidence".

 

"It fails to prove, for instance, that flavours pose any additional health risks or that they attract a significant proportion of non-nicotine users," it said.

 

Hartmann-Boyce said "there is every reason to be concerned about the extent to which the tobacco industry is manipulating the science and messages around new tobacco products."

 

But she warned it was a "difficult balance" to communicate the risks of such products because of the overwhelming damage done by cigarettes. Tobacco kills half its users, according to the World Health Organization.

 

"If we say something is safer than cigarettes, that is not saying it's safe—it's like saying that this knife is safer than a loaded gun," Hartmann-Boyce said.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
PMI Global Communications Chief Moira Gilchrist: Why AI Matters More Than Ever in the Smoke-Free Transition
PMI Global Communications Chief Moira Gilchrist: Why AI Matters More Than Ever in the Smoke-Free Transition
Philip Morris International (PMI) Chief Global Communications Officer Moira Gilchrist said artificial intelligence is changing how companies understand audiences, manage owned information channels and communicate business transformation. PMI is using AI-generated audience personas to test messaging while optimizing its corporate website and other owned channels for large language models. As PMI continues its transition from cigarettes toward smoke-free products, Gilchrist said owned data and corporate channels are becoming increasingly important in demonstrating the scale of that transformation.
Aug.26